Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacogenomics Firm Genetika+ Raises $10M in Series A Round

NEW YORK — Israeli pharmacogenomics firm Genetika+ said on Thursday that it has raised $10 million in a Series A financing round.

The round was led by GreyBird Ventures with participation from Meron Capital, Jumpspeed Ventures, Sapir Venture Partners, and individual investors Howard Morgan and Michael Zeisser.

Genetika+ is developing a test that uses blood-based neurological biomarkers and a patient's genetic and medical history to predict the best antidepressant drug or drug combination for that individual. The company also offers a service to help depression drug developers predict drug responses in patient groups.

Genetika+ said it will use the Series A funding to expand clinical trials of its technology, increase its manufacturing capabilities, and establish a clinical lab in Boston, as well as add employees in Israel and the US.

"Millions of patients around the world face an arduous journey to find the most effective medication to treat their depression," Genetika+ cofounder and CEO Talia Cohen Solal said in a statement. "We're excited to secure this funding, which will enable the first biologically relevant measures to inform potentially life-changing medication selection decisions."

The Scan

Billion-Dollar Diversity Initiative

The Howard Hughes Medical Institute is now accepting applications for its new $1.5 billion initiative to boost the diversity of the scientific workforce.

Biotech Co-Founder Arrested

A co-founder of a Los Angeles-based biotech company has been arrested in connection with a murder-for-hire scheme, according to Endpoint News.

Return of the Tasmanian Tiger

The Washington Post reports that a team in Australia is working to bring the thylacine back from extinction.

Nature Papers on Genome of Individual From Pompeii, CircRNA Study Best Practices, More

In Nature this week: first sequenced genome of a person from Pompeii, best practice guidelines for circRNA studies, and more.